Search research articles
Contact Us
Filters
Showing results (31-40 of 43) with videos related to
Page
of 5
Sort By:
Inflammatory Bowel Diseases
|
September 26, 2025
Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid
Andres Yarur, Peter Irving, Britta Siegmund, et al.
Scientific Reports
|
October 3, 2019
Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients
Suhail Nurbhai, Kevin J Roberts, Timothy M Carlton, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 5, 2015
Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials
Jennifer L Jones, Gilaad G Kaplan, Laurent Peyrin-Biroulet, et al.
The Lancet. Gastroenterology & Hepatology
|
June 20, 2020
British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis
Nick Powell, Hajir Ibraheim, Tim Raine, et al.
Journal of Crohn'S & Colitis
|
April 29, 2017
αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis
Christopher A Lamb, John C Mansfield, Gaik W Tew, et al.
Inflammatory Bowel Diseases
|
February 12, 2026
Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis
David T Rubin, Silvio Danese, Hiroshi Nakase, et al.
The Lancet. Gastroenterology & Hepatology
|
January 14, 2023
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial
Edouard Louis, Matthieu Resche-Rigon, David Laharie, et al.
Inflammatory Bowel Diseases
|
August 21, 2023
Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom
Samuel Hsiang Lim, Beatriz Gros, Esha Sharma, et al.
Alimentary Pharmacology & Therapeutics
|
June 23, 2025
Clinical Utility and Cost-Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine-Induced Myelosuppression: A Genotype-First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource
Christopher Roberts, Jaime Peters, Aleksejs Sazonvos, et al.
Gut
|
January 19, 2026
Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PRognostic effect of Environmental factors in Crohn's and Colitis (PREdiCCt) prospective cohort study
Nathan Constantine-Cooke, Beatriz Gros, Nikolas Plevris, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 43) with videos related to
Sort By:
Page
of 5
Inflammatory Bowel Diseases
|
September 26, 2025
Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid
Andres Yarur, Peter Irving, Britta Siegmund, et al.
Scientific Reports
|
October 3, 2019
Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients
Suhail Nurbhai, Kevin J Roberts, Timothy M Carlton, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 5, 2015
Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials
Jennifer L Jones, Gilaad G Kaplan, Laurent Peyrin-Biroulet, et al.
The Lancet. Gastroenterology & Hepatology
|
June 20, 2020
British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis
Nick Powell, Hajir Ibraheim, Tim Raine, et al.
Journal of Crohn'S & Colitis
|
April 29, 2017
αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis
Christopher A Lamb, John C Mansfield, Gaik W Tew, et al.
Inflammatory Bowel Diseases
|
February 12, 2026
Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis
David T Rubin, Silvio Danese, Hiroshi Nakase, et al.
The Lancet. Gastroenterology & Hepatology
|
January 14, 2023
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial
Edouard Louis, Matthieu Resche-Rigon, David Laharie, et al.
Inflammatory Bowel Diseases
|
August 21, 2023
Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom
Samuel Hsiang Lim, Beatriz Gros, Esha Sharma, et al.
Alimentary Pharmacology & Therapeutics
|
June 23, 2025
Clinical Utility and Cost-Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine-Induced Myelosuppression: A Genotype-First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource
Christopher Roberts, Jaime Peters, Aleksejs Sazonvos, et al.
Gut
|
January 19, 2026
Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PRognostic effect of Environmental factors in Crohn's and Colitis (PREdiCCt) prospective cohort study
Nathan Constantine-Cooke, Beatriz Gros, Nikolas Plevris, et al.
Page
of 5